Langdon L. Miller - Concepedia

Concepedia

Author

Langdon L. Miller

The University of Texas MD Anderson Cancer Center

Also Known As

Langdon L Miller, Langdon L. Miller, Langdon Miller

78

Publications

13.9K

Citations

34

H-Index

54

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Cornell University Sarah Cannon Gilead Sciences (United States)Washington University in St. Louis

LL

About

Langdon L. Miller is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	1.9K
2	Immunology	5	5	148
3	Health Sciences	3	3	55
4	Cell Biology	2	2	33
5	Engineering	1	1	15

Langdon L. Miller

×

60

Publications

13.9K

Citations

34

H-Index

	Year	Citations
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer Leonard B. Saltz, John V. Cox, Charles D. Blanke, New England Journal of Medicine	2000	3K
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia Richard R. Furman, Jeff P. Sharman, Steven Coutré, New England Journal of Medicine	2014	1.7K
PTC124 targets genetic disorders caused by nonsense mutations Ellen Welch, Elisabeth R. Barton, Jin Zhuo, Nature Mendelian DisorderGenetic DisorderGeneticsMolecular GeneticsNonsense Mutations	2007	1.1K
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma Ajay K. Gopal, Brad S. Kahl, Sven de Vos, New England Journal of Medicine	2014	1K
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia Jennifer R. Brown, John C. Byrd, Steven Coutré, Blood	2014	583
Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate Caio M. Rocha Lima, Mark R. Green, Robert Rotche, Journal of Clinical Oncology	2004	580
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia Julia Hoellenriegel, Sarah Meadows, Mariela Sivina, Blood	2011	547
Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial Manfred Kaufmann, Emilio Bajetta, Luc Dirix, Journal of Clinical Oncology	2000	525
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial Eitan Kerem, Samit Hirawat, S. Armoni, The Lancet Ptc124 TreatmentMolecular Diagnostic TechniquesMendelian DisorderPathologyNonsense Mutations	2008	387
The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy Craig M. McDonald, Erik Henricson, Jay J. Han, Muscle & Nerve	2009	386

Page 1